Lapatinib Plus Capecitabine in Women with HER-2–Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial

Cameron, David; Casey, Michelle; Oliva, Cristina; Newstat, B.; Imwalle, Bradley; E. Geyer, Charles

doi:10.1634/theoncologist.2009-0181

Public

Lapatinib Plus Capecitabine in Women with HER-2–Positive Advanced Breast Cancer: Final Survival Analysis of a Phase III Randomized Trial

Published in The Oncologist • Aug 24, 2010

Authors:

David Cameron

Michelle Casey

Cristina Oliva

Abstract

OBJECTIVES: A planned interim analysis of study EGF100151 prompted early termination of enrollment based on a longer time to progression with lapatinib and capecitabine than with capecitabine alone in patients with human epidermal growth factor receptor (HER)-2(+) previously treated advanced breast ...

Subject

Capecitabine

Medicine

Lapatinib

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!